Zacks Research Has Negative Forecast for HALO Q1 Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Stock analysts at Zacks Research lowered their Q1 2025 earnings estimates for Halozyme Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.93 per share for the quarter, down from their prior forecast of […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Stock analysts at Zacks Research lowered their Q1 2025 earnings estimates for Halozyme Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.93 per share for the quarter, down from their prior forecast of […]
